Equillium Revenue
Biotechnology Research • 
San Diego, California, United States • 21-50 Employees
Equillium revenue & valuation
| Annual revenue | $16,600,000 |
| Revenue per employee | $460,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $53,000,000 |
| Total funding | $60,000,000 |
Key Contacts at Equillium
Stephen Connelly
Chief Scientific Officer, Co-Founder
Ellie Bostron Redmond
Associate Director Of Finance
Katherine Xu
Director Of The Board; Member Of Audit Committee
Bruce Steel
Co-Founder & Chief Executive Officer
Geeta Srivastava
Director, Formulation Development & Cmc
Christopher M. Lamb
Director, Accounting
Kham Phenis
Director Clinical Operations
Company overview
| Headquarters | San Diego, California, United States |
| Phone number | +18582401200 |
| Website | |
| NAICS | 541714 |
| SIC | 283 |
| Founded | 2017 |
| Employees | 21-50 |
| Socials |
Equillium Email Formats
Equillium uses 3 email formats. The most common is {first initial}{last name} (e.g., jdoe@equilliumbio.com), used 84.2% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@equilliumbio.com | 84.2% |
{first name}{last name} | johndoe@equilliumbio.com | 10.5% |
{last name}{last name} | doedoe@equilliumbio.com | 5.3% |
About Equillium
Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to pioneer new products with a mission to dramatically improve the lives of patients with severe autoimmune and inflammatory diseases who continue to suffer with high unmet medical needs. By bringing treatments designed to restore the balance of the immune system, we hope to restore the balance of life for patients in need. Our lead product candidate, itolizumab, is a first-in-class monoclonal antibody that targets the CD6-ALCAM signaling pathway, which plays a central role in the activation and trafficking of pathogenic effector T cells that drive inflammation in a number of diseases. We believe itolizumab may have broad therapeutic utility and our current pipeline is focused on developing itolizumab as a best-in-class treatment for multiple severe immuno-inflammatory disorders – this includes acute graft-versus-host disease, SLE / lupus nephritis and uncontrolled asthma.
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
Equillium has 15 employees across 8 departments.
Departments
Number of employees
Funding Data
Explore Equillium's funding history, including investment rounds, total capital raised, and key backers.
Equillium Tech Stack
Discover the technologies and tools that power Equillium's digital infrastructure, from frameworks to analytics platforms.
Video players
Cookie compliance
JavaScript libraries
Maps
CDN
CRM
JavaScript libraries
Security
Analytics
JavaScript libraries
Web frameworks
Denmark
South Africa
United Kingdom
Switzerland
Spain
Germany
Frequently asked questions
4.8
40,000 users
